Upexi (UPXI) Short Interest Ratio & Short Volume

Short interest is the volume of Upexi shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 166,800 shares of UPXI short. 22.07% of Upexi's shares are currently sold short. Learn More on Upexi's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 22.07% of Upexi's floating shares are currently sold short.

Upexi saw a increase in short interest in October. As of October 31st, there was short interest totaling 166,800 shares, an increase of 837.1% from the previous total of 17,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Upexi currently has issued a total of 1,040,000 shares. Some of Upexi's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Upexi currently has a public float of 755,800 shares.

22.07% of Upexi's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Upexi: Pieris Pharmaceuticals, Inc. (1.70%), MIRA Pharmaceuticals, Inc. (12.65%), GlycoMimetics, Inc. (8.75%), Spruce Biosciences, Inc. (0.56%), Cyclo Therapeutics, Inc. (0.69%), Unity Biotechnology, Inc. (1.97%), MEI Pharma, Inc. (1.23%), ProPhase Labs, Inc. (0.65%), Enlivex Therapeutics Ltd. (0.75%), Cognition Therapeutics, Inc. (2.41%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling UPXI is an investing strategy that aims to generate trading profit from Upexi as its price is falling. UPXI shares are trading up $0.43 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Upexi occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of UPXI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including UPXI, twice per month. The most recent reporting period available is October, 31 2024.